# OnCo record localised-adrenocortical-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/localised-adrenocortical-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "localised-adrenocortical-carcinoma" ;
  schema:name "Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)"@en ;
  schema:alternateName "Resectable adrenocortical carcinoma"@en, "Early-stage ACC"@en, "Non-metastatic adrenal cortical carcinoma"@en, "Adrenocortical carcinoma after complete resection"@en ;
  schema:description "Localised adrenocortical carcinoma is adrenal cortex cancer still confined to the adrenal gland and its surroundings that surgery can remove, the only treatment that cures it. Afterwards the adrenal-specific drug mitotane is given to patients whose tumour has a high risk of returning, judged by the Ki-67 index and whether it was completely removed, while low-risk patients are watched."@en ;
  schema:url <https://onco.cc/cancers/localised-adrenocortical-carcinoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Adrenocortical_carcinoma> ;
  schema:citation <https://doi.org/10.1016/S2213-8587(23)00193-6>, <https://doi.org/10.1530/EJE-18-0608>, <https://en.wikipedia.org/wiki/Adrenocortical_carcinoma> ;
  onco:tag "subtype-page", "endocrine" ;
  onco:related <https://onco.cc/cancers/advanced-adrenocortical-carcinoma/>, <https://onco.cc/cancers/adrenocortical/>, <https://onco.cc/cancers/hereditary-ppgl/> ;
  onco:technologies <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/fdg-pet/> ;
  onco:targets <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/mitotane/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:terms <https://onco.cc/terms/adrenalectomy/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/staging-systems/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-adiuvo-adjuvant-mitotane-acc-lancet-diabetes-endocrinol-2023/>, <https://onco.cc/key-papers/paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018/> ;
  onco:pipeline <https://onco.cc/drugs/mitotane/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:standardOfCare <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/adrenalectomy/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/mitotane/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/drugs/mitotane/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/terms/adrenalectomy/>, <https://onco.cc/technologies/thermal-ablation/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/mitotane/> .